Genelux to license cancer immunotherapy product

Immunotherapy firm, Genelux Corporation, has entered a licensing agreement with ELIAS Animal Health for its V-VET1, a vaccinia viral strain. The clinical-stage product is intended to replicate in cancer cells causing the death of cancer cells. ELIAS specializes in veterinary cancer care that uses T-cell immunotherapy. 

Cancer is the top reason dogs die in the US, and treatment options often do not prolog life for a significant length of time. The therapy being investigated in a Phase 1 study will be given to dogs with varied types of cancer, including anal glad carcinoma, mast cell tumors, osteosarcoma, soft tissue sarcoma, and T-cell lymphoma. During the study, a maximum tolerated dose was not found as dogs were able to handle the dosages well, and disease control and responses were found. 

"We are excited to be working with ELIAS Animal Health to advance V-VET1 for the treatment of dogs and other non-human animals with various cancers," said Thomas Zindrick, president and chief executive officer of Genelux. "Unfortunately, few veterinary-only drugs currently exist to treat companion animals with cancer. ELIAS is doing tremendous work to advance novel treatments for animal health, including cutting-edge adoptive T cell therapy combined with surgery and radiotherapy, and we are proud to partner with them."

The agreement between ELIAS and Genelux will provide the latter with funding at the outset and at predetermined sales and development milestones. After reaching the market, Genelux will receive royalties on sales of its product. 

  • Please enter a comment

Name *
Email address *
Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

More news

WVC Annual Conference 2024


Diagnostic accuracy of plain radiography to identify synovial penetration in horses with traumatic limb wounds


Effects of administration of vitamin C on oxidative status in healthy horses


Viticus Group 96th WVC Annual Conference is Back – It’s Time to Vet Differently


Exocrine pancreatic insufficiency in dogs and cats




News of interest


Copyright © 2024 - All Rights Reserved
ISSN 2768-198X